USFDA Approval March 27, 2006 Zidovudine Capsules 100 mg Aurobindo Pharma, Ltd. 1

First Page		Document Content
Date: 2009-12-08 04:25:32 Organofluorides Bristol-Myers Squibb Azides Zidovudine Antiretroviral drug Stavudine Ribavirin Reverse-transcriptase inhibitor Hepatitis Chemistry Pharmacology Medicine		USFDA Approval March 27, 2006 Zidovudine Capsules 100 mg Aurobindo Pharma, Ltd. 1 Add to Reading List Source URL: apps.who.int Download Document from Source Website File Size: 156,60 KB Share Document on Facebook

	Acute Hepatitis C in the PROUD pilot study Juan Tiraboschi, Liz Brodnicki, Brady Michael, John Saunders, Schembri Gabriel, Mark Roche, Julie Fox on behalf of the PROUD study DocID: 1vngt - View Document
	PRESS RELEASE AbbVie Receives Health Canada Approval of HOLKIRATM PAK for the Treatment of Chronic Genotype 1 Hepatitis C  New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for geno DocID: 1vlwz - View Document
	PRESS RELEASE AbbVie’s MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes    DocID: 1vjI2 - View Document
	APASL and CEVHAP Partnership: a Hepatitis-Free World November DocID: 1vgwC - View Document
	California Institute of Technology Hepatitis B Vaccination Offer Form Occupational Exposure to Bloodborne Pathogens Please complete this form if you may come in contact with human blood or other potentially infectious hu DocID: 1vf93 - View Document